Treatment of chronic hepatitis B in HIV-infected persons: Thinking outside the black box

Clinical Infectious Diseases

Volumn 41, Issue 7, 2005, Pages 1035-1040

  Thio, Chloe L ^a,b   Sulkowski, Mark S ^a   Thomas, David L ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b NONE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADEFOVIR; ALPHA INTERFERON; ANTIRETROVIRUS AGENT; EMTRICITABINE; ENTECAVIR; LAMIVUDINE; PEGINTERFERON; PEGINTERFERON ALPHA2B; TENOFOVIR DISOPROXIL;

ANTIVIRAL ACTIVITY; CLINICAL TRIAL; DRUG APPROVAL; DRUG EFFICACY; DRUG LABELING; DRUG RESISTANCE; HEPATITIS B; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LIVER TOXICITY; MIXED INFECTION; PRIORITY JOURNAL; REVIEW;

ANTIVIRAL AGENTS; HEPATITIS B, CHRONIC; HIV INFECTIONS; HUMANS;

EID: 25444463273     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/496921     Document Type: Review

References (54)

1. Rustgi VK, Hoofnagle JH, Gerin JL, et al. Hepatitis B virus infection in the acquired immunodeficiency syndrome. Ann Intern Med 1984; 101:795-7.
2. Homann C, Krogsgaard K, Pedersen C, Andersson P, Nielsen JO. High incidence of hepatitis B infection and evolution of chronic hepatitis B infection in patients with advanced HIV infection. J Acquir Immune Defic Syndr 1991; 4:416-20.
3. Otegbayo JA, Fasola FA, Abja A. Prevalence of hepatitis B surface and e antigens, risk factors for viral acquisition and serum transaminase among blood donors in Ibadan, Nigeria. Trop Gastroenterol 2003; 24:196-7.
4. Sud A, Singh J, Dhiman RK, Wanchu A, Singh S, Chawla Y. Hepatitis B virus co-infection in HIV infected patients. Trop Gastroenterol 2001; 22:90-2.
5. Thio CL, Seaberg EC, Skolasky RL, et al. HIV-1, hepatitis B virus, and risk of liver-related mortality in the Multicenter AIDS Cohort Study (MACS). Lancet 2002; 360:1921-6.
6. Wit FW, Weverling GJ, Weel J, Jurriaans S, Lange JM. Incidence of and risk factors for severe hepatotoxicity associated with antiretroviral combination therapy. J Infect Dis 2002; 186:23-31.
7. den Brinker M, Wit FW, Wertheim-van Dillen PM, et al. Hepatitis B and C virus co-infection and the risk for hepatotoxicity of highly active antiretroviral therapy in HFV-1 infection. AIDS 2000; 14:2895-902.
8. Saves M, Raffi F, Clevenbergh P, et al. Hepatitis B or hepatitis C virus infection is a risk factor for severe hepatic cytolysis after initiation of a protease inhibitor-containing antiretroviral regimen in human immunodeficiency virus-infected patients. The APROCO Study Group. Antimicrob Agents Chemother 2000; 44:3451-5.
9. Law WP, Dore GJ, Duncombe CJ, et al. Risk of severe hepatotoxicity associated with antiretroviral therapy in the HIV-NAT Cohort, Thailand, 1996-2001. AIDS 2003; 17:2191-9.
10. Saves M, Vandentorren S, Daucourt V, et al. Severe hepatic cytolysis: incidence and risk factors in patients treated by antiretroviral combinations. Aquitaine Cohort, France, 1996-1998. Groupe dEpidemiologie Clinique de Sida en Aquitaine (GECSA). AIDS 1999; 13:F115-21.
11. Drake A, Mijch A, Sasadeusz J. Immune reconstitution hepatitis in HIV and hepatitis B coinfection, despite lamivudine therapy as part of HAART. Clin Infect Dis 2004; 39: 129-32.
12. Bessesen M, Ives D, Condreay L, Lawrence S, Sherman KE. Chronic active hepatitis B exacerbations in human immunodeficiency virus-infected patients following development of resistance to or withdrawal of lamivudine. Clin Infect Dis 1999; 28:1032-5.
13. Torriani FJ, Rodriguez-Torres M, Rockstroh JK, et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection in HIV-infected patients. N Engl J Med 2004; 351: 438-50.
14. Marcellin P, Lau GKK, Bonino F, et al. Peg-interferon alfa-2a (40KDa) (Pegasys) monotherapy is more effective than lamivudine monotherapy in the treatment of HBeAg negative chronic hepatitis B: 72 week results from a phase III, partially double-blind study of Pegasys alone vs. Pegasys plus lamivudine vs. lamivudine [abstract 95]. In: Program and abstracts of the 39th Meeting of the European Association for the Study of Liver Disease (Berlin). Geneva, Switzerland: Keyes International, 2004.
15. Viread (tenofovir disoproxil fumarate) [package insert]. Gilead Sciences: Foster CA, 2005.
16. Benson CA, Kaplan JE, Masur H, Pau A, Holmes KK. Treating opportunistic infections among HIV-infected adults and adolescents. MMWR Recomm Rep 2004; 53(RR-15): 1-112
17. erratum: MMWR Morb Mortal Wkly Rep 2005; 54:311.
18. Alberti A, Clumeck N, Collins S, et al. Short statement of the first European Consensus Conference on the treatment of chronic hepatitis B and C in HIV-coinfected patients. J Hepatol 2005; 42:615-24.
19. Wong DK, Cheung AM, O'Rourke K, Naylor DC, Detsky AS, Heathcote J. Effect of alfa-interferon treatment in patients with hepatitis B e antigen-positive chronic hepatitis B. Ann Intern Med 1993; 119:312-23.
20. Wong DK, Yim C, Naylor CD, et al. Interferon alfa treatment of chronic hepatitis B: randomized trial in a predominantly homosexual male population. Gastroenterology 1995; 108: 165-71.
21. McDonald JA, Caruso L, Karayiannis P, et al. Diminished responsiveness of male homosexual chronic hepatitis B virus carriers with HTLV-III antibodies to recombinant alpha-interferon. Hepatology 1987; 7:719-23.
22. Dimartino V, Thevenot T, Boyer N, Degos F, Marcellin P. Serum alanine transaminase level is a good predictor of response to interferon alfa therapy for chronic hepatitis B in human immunodeficiency virus-infected patients. Hepatology 2000; 31:1030-1.
23. Di Martino V, Lunel F, Cadranel JF, et al. Long-term effects of interferon-alpha in five HIV-positive patients with chronic hepatitis B. J Viral Hepat 1996; 3:253-60.
24. Marcellin P, Boyer N, Colin JF, et al. Recombinant alpha interferon for chronic hepatitis B in anti-HIV positive patients receiving zidovudine. Gut 1993; 34:5106.
25. Zylberberg H, Jiang J, Pialoux G, et al. Alpha-interferon for chronic active hepatitis B in human immunodeficiency virus-infected patients. Gastroenterol Clin Biol 1996; 20: 968-71.
26. Visco G, Alba L, Grisetti S, et al. Zidovudine plus interferon alfa-2b treatment in patients with HIV and chronic active viral hepatitis. Gut 1993; 34:S107-8.
27. Cooksley WG, Piratvisuth T, Lee S-D, et al. Peginterferon alpha-2a (40 kDa): an advance in the treatment of hepatitis B e antigen-positive chronic hepatitis B. J Viral Hepat 2003; 10:298-305.
28. Dienstag JL, Schiff ER, Wright TL, et al. Lamivudine as initial treatment for chronic hepatitis B in the United States. N Engl J Med 1999; 341:1256-63.
29. Benhamou Y, Bochet M, Thibault V, et al. Long-term incidence of hepatitis B virus resistance to lamivudine in human immunodeficiency virus-infected patients. Hepatology 1999; 30:1302-6.
30. Lok AS, Lai CL, Leung N, et al. Long-term safety of lamivudine treatment in patients with chronic hepatitis B. Gastroenterology 2003; 125:1714-22.
31. Harris J, Snow A, Borroto-Esoda K, et al. Emtricitabine therapy for hepatitis infection in HIV-1 patients co-infected with hepatitis B: antiviral response and genotypic findings in antiretroviral treatment naive patients [abstract 836], In: Program and abstracts of the 11th Conference on Retro viruses and Opportunistic Infections (San Francisco). Alexandria, VA: Foundation for Retrovirology and Human Health, 2004.
32. Baraclude (entecavir) [package insert]. Bristol Myers-Squibb: Princeton, NJ, 2005.
33. Pessoa W, Gazzard B, Huang A, et al. Entecavir in HIV/HBV co-infected patients: safety and efficacy in a phase II study (ETV-038) [abstract 123]. In: Program and abstracts of the 12th Conference on Retroviruses and Opportunistic Infections (Boston). Alexandria, VA: Foundation for Retrovirology and Human Health, 2005.
34. Benhamou Y, Thibault V, Calvez V, et al. Three-year treatment with adefovir dipivoxil in chronic hepatitis B patients with lamivudine-resistant HBV and HIV co-infection results in significant and sustained clinical improvement [abstract 835]. In: Program and abstracts of the 11th Conference on Retroviruses and Opportunistic Infections (San Francisco). Alexandria, VA: Foundation for Retrovirology and Human Health, 2004.
35. Benhamou Y, Thibault V, Vig P, et al. Long-term treatment with adefovir dipivoxil 10 mg (ADV) in patients with lamivudine-resistant (LAM-R) HBV and HIV co-infection results in significant and sustained clinical improvement [abstract WeOrA1329]. In: Program and abstracts of the 15th International AIDS Conference (Bangkok). Stockholm: International AIDS Society, 2004.
36. Angus P, Vaughan RD, Xiong S, et al. Resistance to adefovir dipivoxil therapy associated with development of a novel mutation in the HBV polymerase. Gastroenterology 2003; 125: 292-7.
37. Delaney WE, Yang H, Miller MD, Gibbs CS, Xiong S. Combinations of adefovir with nucleoside analogs produce additive antiviral effects against hepatitis B virus in vitro. Antimicrob Agents Chemother 2004; 48:3702-10.
38. Lada O, Benhamou Y, Cahour A, Katlama C, Poynard T, Thibault V. In vitro susceptibility of lamivudine-resistant hepatitis B virus to adefovir and tenofovir. Antivir Ther 2004; 9: 353-63.
39. Cooley L, Ayres A, Bartholomeusz A, et al. Prevalence and characterization of lamivudine-resistant hepatitis B virus mutations in HIV-HBV co-infected individuals. AIDS 2003; 17:1649-57.
40. Peters M, Anderson J, Lynch P, et al. Tenofovir disoproxil fumarate is not inferior to adefovir dipivoxil for the treatment of hepatitis B virus in subjects who are co-infected with HIV: results of aCTG A5127 [abstract 124]. In: Program and abstracts of the 12th Conference on Retroviruses and Opportunistic Infections (Boston). Alexandria, VA: Foundation for Retrovirology and Human Health, 2005.
41. Van Bommel F, Wunsche T, Mauss S, et al. Comparison of adefovir and tenofovir in the treatment of lamivudine-resistant hepatitis B virus infection. Hepatology 2004; 40:1421-5.
42. Dore GJ, Cooper DA, Pozniak AL, et al. Efficacy of tenofovir disoproxil fumarate in antiretroviral therapy-naive and -experienced patients coinfected with HIV-1 and hepatitis B virus. J Infect Dis 2004; 189:1185-92.
43. Kuo A, Dienstag JL, Chung RT. Tenofovir disoproxil fumarate for the treatment of lamivudine-resistant hepatitis B. Clin Gastroenterol Hepatol 2004; 2:266-72.
44. Van Bommel F, Schernick A, Hopf U, Berg T. Tenofovir disoproxil fumarate exhibits strong antiviral effect in a patient with lamivudine-resistant severe hepatitis B reactivation. Gastroenterology 2003; 124:586-7.
45. Benhamou Y, Tubiana R, Thibault V. Tenofovir disoproxil fumarate in patients with HIV and lamivudine-resistant hepatitis B virus. N Engl J Med 2003; 348:177-8.
46. Nelson M, Portsmouth S, Stebbing J, et al. An open-label study of tenofovir in HIV-1 and hepatitis B virus co-infected individuals. AIDS 2003; 17:F7-10.
47. Ristig MB, Crippin J, Aberg JA, et al. Tenofovir disoproxil fumarate therapy for chronic hepatitis B in human immunodeficiency virus/hepatitis B virus-coinfected individuals for whom interferon-alpha and lamivudine therapy have failed. J Infect Dis 2002; 186:1844-7.
48. Nunez M, Perez-Olmeda M, Diaz B, Rios P, Gonzalez-Lahoz J, Soriano V. Activity of tenofovir on hepatitis B virus replication in HIV-co-infected patients failing or partially responding to lamivudine. AIDS 2002; 16: 2352-4.
49. Van Bommel F, Wunsche T, Schurmann D, Berg T. Tenofovir treatment in patients with lamivudine-resistant hepatitis B mutants strongly affects viral replication. Hepatology 2002; 36:507-8.
50. Bani-Sadr F, Palmer P, Scieux C, Molina JM. Ninety-six-week efficacy of combination therapy with lamivudine and tenofovir in patients coinfected with HIV-1 and wild-type hepatitis B virus. Clin Infect Dis 2004; 39:1062-4.
51. Piketty C, Pellegrin I, Katlama C, et al. Efficacy of tenofovir disoproxil fumarate in hepatitis B virus in HIV-co-infected patients: the TECOVIR Study [abstract 834]. In: Program and abstracts of the 11th Conference on Retroviruses and Opportunistic Infections (San Francisco). Alexandria, VA: Foundation for Retrovirology and Human Health, 2004.
52. Trimoulet P, Thibault V, Schneider V, et al. Anti-hepatitis B virus activity of tenofovir disoproxil fumarate in human immunodeficiency virus co-infected subjects [abstract 2467]. In: Program and abstracts of the 43rd Interscience Conference on Antimicrobial Agents and Chemotherapy (Chicago). Washington, DC: American Society for Microbiology, 2003.
53. Stephan C, Berger A, Lutz T, et al. Impact of tenofovir on chronic hepatitis B in HIV coinfected individuals: the Frankfurt Cohort Study experience [abstract V-784]. In: Program and abstracts of the 43rd Interscience Conference on Antimicrobial Agents and Chemotherapy (Chicago, IL). Washington, DC: American Society for Microbiology, 2003:496.
54. Gilleece Y, Nelson M, Clarke A, et al. Tenofovir in the treatment of hepatitis B/HIV co-infected individuals [abstract 3298]. In: Program and abstracts of the 15th International AIDS Conference (Bangkok). Stockholm: International AIDS Society, 2004.